Praxis Precision Medicines/$PRAX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Ticker
$PRAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
116
ISIN
US74006W2070
Website
PRAX Metrics
BasicAdvanced
$943M
-
-$10.79
2.67
-
Price and volume
Market cap
$943M
Beta
2.67
52-week high
$91.83
52-week low
$26.70
Average daily volume
289K
Financial strength
Current ratio
12.42
Quick ratio
8.299
Long term debt to equity
0.243
Total debt to equity
0.243
Profitability
EBITDA (TTM)
-232.714
Gross margin (TTM)
-2,192.97%
Net profit margin (TTM)
-2,617.11%
Operating margin (TTM)
-2,868.84%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-39.95%
Return on equity (TTM)
-63.56%
Valuation
Price to revenue (TTM)
112.319
Price to book
2.14
Price to tangible book (TTM)
2.15
Price to free cash flow (TTM)
-5.566
Free cash flow yield (TTM)
-17.97%
Free cash flow per share (TTM)
-832.26%
Growth
Revenue change (TTM)
270.02%
Earnings per share change (TTM)
-20.93%
3-year earnings per share growth (CAGR)
-46.56%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
Bulls say / Bears say
Praxis Precision Medicines' drug candidate, Relutrigine, demonstrated a significant 46% reduction in motor seizures in a Phase 2 study, with over 30% of patients achieving complete seizure freedom, indicating strong potential for future approvals and market adoption. (Investing.com)
Analyst firms such as Needham have raised their price targets for Praxis, with Needham increasing its target to $151, reflecting confidence in the company's growth prospects. (Investing.com)
Praxis stock has reached a new 52-week high of $68, marking a 225.49% increase over the past year, indicating strong investor confidence and market performance. (Investing.com)
Despite positive study results, the market reaction to Relutrigine's Phase 2 data was more subdued than anticipated, suggesting potential investor skepticism or concerns about future developments. (Investing.com)
Praxis reported a quarterly adjusted loss of $2.94 per share for the quarter ended December 31, higher than the same quarter last year, indicating ongoing financial challenges. (TradingView News)
Analyst firms such as Robert W. Baird have lowered their price targets for Praxis, with Baird reducing its target from $117.00 to $73.00, reflecting concerns about the company's future performance. (Techdows News)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
PRAX News
AllArticlesVideos
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·17 hours ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $943M as of July 03, 2025.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of July 03, 2025.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.